Suchergebnisse - (Subject:"Adalimumab")

PubPharm (80)

1

M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis

enthalten in: Arthritis and rheumatism | 2013

von Ammitzbøll, C. | Thiel, S. | Jensenius, J. | +7

2

Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare

enthalten in: Arthritis and rheumatism | 2013

von Haibel, H. | Heldmann, F. | Braun, J. | +3

3

Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis

enthalten in: Arthritis and rheumatism | 2013

von Binder, N. | Puchner, A. | Niederreiter, B. | +6

4

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis : findings of a phase IIIb, multinational, prospective, randomized study

enthalten in: Arthritis and rheumatism | 2013

von Weinblatt, M. | Schiff, M. | Valente, R. | +5

CommentIn: Nat Rev Rheumatol. 2013 Jan;9(1):1. - PMID 23229451

5

Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

enthalten in: Arthritis and rheumatism | 2012

von Krieckaert, C. | Jamnitski, A. | Nurmohamed, M. | +3

6

Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors : drug-specific comparisons in the Swedish Biologics Register

enthalten in: Arthritis and rheumatism | 2012

von Simard, J. | Neovius, M. | Askling, J. | +12

CommentIn: Arthritis Rheum. 2013 Jun;65(6):1671-2. - PMID 23508884

7

Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy

enthalten in: Arthritis and rheumatism | 2012

von McGovern, J. | Nguyen, D. | Notley, C. | +3

8

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

enthalten in: Arthritis and rheumatism | 2012

von Fleischmann, R. | Cutolo, M. | Genovese, M. | +9

9

Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints

enthalten in: Arthritis and rheumatism | 2011

von Aletaha, D. | Smolen, J.

10

Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors : a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover

enthalten in: Arthritis and rheumatism | 2011

von Pedersen, S. | Sørensen, I. | Lambert, R. | +17

1
2
3
4
5
6
7
8
Nächster »
[8]